Moderna (CHIX:0QFD) Valuation Rank


CHIX:0QFD Moderna Inc CHIX:0QFD
58 GF Score
Price €42.71
GF Value €14.56
! 7 Warning Signs
View Full Analysis

What is Moderna Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Moderna Valuation Rank Related Terms

CHIX:0QFD
58GF Score
Moderna Inc CHIX:0QFD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moderna (CHIX:0QFD) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €42.71 is trading 193.3% above its estimated GF Value™ of €14.56.

Key valuation signals for CHIX:0QFD:

  • Valuation Rank:
  • GF Value™: €14.56 vs. price of €42.71 (193.3% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
58GF Score

Get the complete analysis for CHIX:0QFD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.71
Price
€14.56
GF Value